Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells

Zhang, Lu; Ma, Xiao-Jing-Nan; Fei, Yuan-Yuan; Han, Hengtong; Xu, Jun; Cheng, Lü; Li, Xun

doi:10.1016/j.pharmthera.2021.108004

Cited by 52 publications

(25 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These pluripotent stem cells not only have great potential for regeneration medicine, but also provide the opportunity to study and understand human development as they have the capacity to differentiate into all three germ layer-derived cells and are syngeneic they have an unlimited capacity for self-renewal and can differentiate into derivatives of all three embryonic germ layers (i.e., ectoderm, mesoderm and endoderm) [ 8 – 17 ]. Developing a better understanding of the underlying mechanisms of pluripotency and differentiation is pretty important, because it can provide knowledge that will allow specific manipulation of the development of human cells, to direct stem cells for generating specific cells types, and to understand abnormal cell development in conditions such as cancers [ 8 – 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…Various experimental techniques, including somatic cell nuclear transfer [ 1 ], human embryonic stem cell (ESC) microenvironment [ 3 ], cell fusion [ 36 ] and somatic cell reprogramming with defined transcription factors [ 6 , 7 ], have been developed for deriving pluripotent stem cells. Many routing protocols have been developed to maintain the self-renewal of stem cells [ 8 – 17 ]. However, maintaining the pluripotent stem cells in culture is a tedious and expensive task.…”

Section: Discussionmentioning

confidence: 99%

“…Pluripotency of stem cells can be identified by RT-PCR of ESC markers (i.e. Oct4, Sox2 and Nanog, immunofluorescence staining with stage-specific embryonic antigens (Oct4, Sox2, Nanog, SSEA-3, SSEA-4, TRA-l-60 and TRA-1-81), alkaline phosphatase activity and teratoma assay [ 8 – 17 ]. However, these approaches often involve destruction or fixation of cells during assay, and can’t be employed to real-time monitor the pluripotency of live cells [ 29 – 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, close monitoring the changing pluripotency of stem cells in live cells is essential for many studies [ 29 – 35 ]. The following assays for the pluripotency of stem cells, such as RT-PCR of ESC markers, immunofluorescence staining with stage-specific embryonic antigens, alkaline phosphatase activity and teratoma assay, can’t real-time monitor the pluripotency changes in live cells [ 8 – 17 ]. Here, we described a pluripotency monitoring system, in which the expression of enhanced green fluorescent protein (EGFP) is under the control of the promoter of a pluripotency gene (i.e., Oct4).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A real-time pluripotency reporter for the long-term and real-time monitoring of pluripotency changes in induced pluripotent stem cells

Shen

Lü

Huang

et al. 2022

Aging

View full text Add to dashboard Cite

To master the technology of reprogramming mouse somatic cells to induced pluripotent stem cells (iPSCs), which will lay a good foundation for setting up a technology platform on reprogramming human cancer cells into iPSCs. Mouse iPSCs (i.e., Oct4-GFP miPSCs) was successfully generated from mouse embryonic fibroblasts (MEFs) harboring Oct4-EGFP transgene by introducing four factors, Oct4, Sox2, c-Myc and Klf4, under mESC (Murine embryonic stem cells) culture conditions. Oct4-GFP miPSCs were similar to mESCs in morphology, proliferation, mESC-specific surface antigens and gene expression. Additionally, Oct4-GFP miPSCs could be cultured in suspension to form embryoid bodies (EBs) and differentiate into cell types of the three germ layers in vitro . Moreover, Oct4-GFP miPSCs could develop to teratoma and chimera in vivo . Unlike cell cycle distribution of MEFs, Oct4-GFP miPSCs are similar to mESCs in the cell cycle structure which consists of higher S phase and lower G1 phase. More importantly, our data demonstrated that MEFs harboring Oct4-EGFP transgene did not express GFP, until they were reprogrammed to the pluripotent stage (iPSCs), while the GFP expression was progressively lost when these pluripotent Oct4-GFP miPSCs exposed to EB-mediated differentiation conditions, suggesting the pluripotency of Oct4-GFP miPSCs can be real-time monitored over long periods of time via GFP assay. Altogether, our findings demonstrate that Oct4-GFP miPSC line is successfully established, which will lay a solid foundation for setting up a technology platform on reprogramming cancer cells into iPSCs. Furthermore, this pluripotency reporter system permits the long-term real-time monitoring of pluripotency changes in a live single-cell, and its progeny.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A real-time pluripotency reporter for the long-term and real-time monitoring of pluripotency changes in induced pluripotent stem cells

Shen

Lü

Huang

et al. 2022

Aging

View full text Add to dashboard Cite

show abstract

“…In addition to exosomes, mesenchymal stem cells (MSCs) have recently been developed for treatment of liver injury [ 305 ]. MSCs release a variety of cytokines, such as hepatocyte growth factor (HGF), through paracrine mechanisms.…”

Section: Anti-inflammatory Nanodrugsmentioning

confidence: 99%

Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury

Liu

Huang

Zhu

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Liver organoids: From 3D printing to biomedical applications

Shi,

Han,

Zhang

et al. 2024

BMEMat

View full text Add to dashboard Cite

The liver is an immune organ, especially an immune tolerance organ. The critical shortage of donor organs and disease models for the treatment of end‐stage liver failure underscores the urgent need for the generation of liver organoids from human induced pluripotent stem cells (iPSCs). Notably, significant advancements have been made in the study of liver organoids over the past decade. The construction of liver organoids has transitioned from single cell type to multicellular models, and from two‐dimensional to three‐dimensional cultures. Here we provide the progress surrounding the different liver organoids culture techniques from 3D printing to organ‐on‐chip, as well as focuses on the present and future applications of liver organoids, and then to present challenges and perspectives ahead for further advancement.

show abstract

Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells

Cited by 52 publications

References 190 publications

A real-time pluripotency reporter for the long-term and real-time monitoring of pluripotency changes in induced pluripotent stem cells

A real-time pluripotency reporter for the long-term and real-time monitoring of pluripotency changes in induced pluripotent stem cells

Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury

Liver organoids: From 3D printing to biomedical applications

Contact Info

Product

Resources

About